Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States
To examine demographic and geographic variation in the use of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Medicare beneficiaries. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - October 27, 2017 Category: Opthalmology Authors: Emily W. Gower, Joshua D. Stein, Nakul S. Shekhawat, Shravani Mikkilineni, Taylor S. Blachley, Nicholas M. Pajewski Tags: Original Articles Source Type: research

Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: A Bayesian network meta-analysis.
CONCLUSION: There was no apparent difference on improving vision between SDMLP monotherapy and CLP monotherapy. The most effective treatment in the network was ranibizumab therapy combined with CLP followed by SDMLP monotherapy, Bevacizumab therapy combined with CLP, and CLP monotherapy in rank order. PMID: 29091878 [PubMed - as supplied by publisher] (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 26, 2017 Category: Drugs & Pharmacology Authors: Wu Y, Ai P, Ai Z, Xu G Tags: Biomed Pharmacother Source Type: research

Laser-Induced Choroidal Neovascularizations: Clinical Study of 3 Cases
Conclusion: To prevent a laser-induced CNV, it is critical to avoid heavy small-spot laser burns and repeated application. Patients should be monitored carefully for CNV after laser treatment. In our cases, PDT and intravitreal ranibizumab injections were effective for the treatment of laser-induced CNV.Case Rep Ophthalmol 2017;8:429 –435 (Source: Case Reports in Ophthalmology)
Source: Case Reports in Ophthalmology - October 25, 2017 Category: Opthalmology Source Type: research

Risk for low visual acuity after 1 and 2 years of treatment with ranibizumab or bevacizumab for patients with neovascular age-related macular degeneration
Conclusion:Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively. (Source: RETINA)
Source: RETINA - October 25, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization
Conclusion:Intravitreal ranibizumab was safe and effective for treating myopic choroidal neovascularization. Only 44% of eyes required retreatment after the first year, and vision improved in more than 60% of eyes over 5 years. (Source: RETINA)
Source: RETINA - October 25, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Retinal pigment epithelial atrophy after anti–vascular endothelial growth factor injections for retinal angiomatous proliferation
Conclusion:Retinal pigment epithelial atrophy developed in 36.6% during 12 months after anti-VEGF treatment for retinal angiomatous proliferation. The presence of refractile drusen at baseline was identified as a novel significant risk factor for RPE atrophy development. (Source: RETINA)
Source: RETINA - October 25, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema
Conclusions: Three treatment methods had similar effects with regard to improvement in VA; however, intravitreal triamcinolone provided additional anatomical improvement.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - October 25, 2017 Category: Opthalmology Source Type: research

Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab
Conclusions: Age and the T allele ofARMS2A69S are the risk factors requiring retreatments, leading to poor visual change in eyes with exudative AMD following the initial 3-monthly IVR.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - October 25, 2017 Category: Opthalmology Source Type: research

Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents
Purpose: To compare changes of retinal morphology in the first weeks following injection of anti-VEGF agents for neovascular age-related macular degeneration (nAMD).Procedures: In a prospective study 50 patients with active choroidal neovascularization secondary to nAMD were monitored weekly by spectral-domain optical coherence tomography for 3 weeks after treatment. Twenty-two patients received bevacizumab, 15 ranibizumab, and 13 aflibercept. Morphological parameters of retinal compartments were compared.Results: Mean central retinal thickness (391.22 ± 123.41 µm) was reduced by -26.15 µm (p (Source: Ophthalmologica)
Source: Ophthalmologica - October 25, 2017 Category: Opthalmology Source Type: research

Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice
Purpose: Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab.Methods: We conducted a retrospective study evaluating outcomes of multiple DEX injections and those requiring conversion to ranibizumab at Moorfields Eye Hospital, Bedford, UK. All patients had undergone a complete ophthalmic work-up.Results: Patients (n = 129) had a mean follow-up of 19.9 months. The mean improvement in central retinal thickness was 312 μm after final DEX (p = (Source: Ophthalmologica)
Source: Ophthalmologica - October 25, 2017 Category: Opthalmology Source Type: research

Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography
(Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - October 25, 2017 Category: Opthalmology Authors: Jung Kee Min, Seunghwan Lee, Jong Hoon Park, Je Moon Woo, Hyun Seung Yang Tags: Letter to the Editor Source Type: research

Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography
Acta Ophthalmologica, EarlyView. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - October 25, 2017 Category: Opthalmology Source Type: research

Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone
Abstract PurposeTo evaluate detailed changes in retinal layer thickness in spectral‐domain optical coherence tomography (SD‐OCT) images during a 1‐year follow‐up of patients treated for diabetic macula oedema (DME). MethodsPost hoc analysis of retinal layer thickness changes applying the automated layer segmentation of SD‐OCT images in eyes with DME that were randomly assigned to receive pro re nata (PRN) treatment with either 0.5 mg ranibizumab or 8 mg triamcinolone. In each patient, seven retinal layers were segmented in 49 scans covering a 20° × 20° area of the macula at basel...
Source: Acta Ophthalmologica - October 24, 2017 Category: Opthalmology Authors: Sonja G. Prager, Jan Lammer, Christoph Mitsch, Julia Hafner, Berthold Pemp, Christoph Scholda, Michael Kundi, Ursula Schmidt ‐Erfurth, Katharina Kriechbaum Tags: Original Article Source Type: research

Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone
Acta Ophthalmologica,Volume 96, Issue 2, Page e195-e200, March 2018. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - October 24, 2017 Category: Opthalmology Source Type: research

Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema
Conclusions: Three treatment methods had similar effects with regard to improvement in VA; however, intravitreal triamcinolone provided additional anatomical improvement.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - October 19, 2017 Category: Opthalmology Source Type: research

Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab
Conclusions: Age and the T allele ofARMS2A69S are the risk factors requiring retreatments, leading to poor visual change in eyes with exudative AMD following the initial 3-monthly IVR.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - October 18, 2017 Category: Opthalmology Source Type: research

VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema
ConclusionsThere is no association between the studied VEGF-A SNVs and the responses to IVR therapy in DME. However, the VEGF-A rs833069 gene polymorphism has a clear association with the severity of diabetic retinopathy. (Source: International Ophthalmology)
Source: International Ophthalmology - October 13, 2017 Category: Opthalmology Source Type: research

Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T
Purpose of review The aim of this study was to provide clinically relevant findings from the DRCR.net Protocol T, a multicentre randomized clinical trial comparing intravitreous aflibercept, repackaged (compounded) bevacizumab and ranibizumab for vision-impairing centre-involved diabetic macular oedema (DME). Recent findings At 1 year, all three antivascular endothelial growth factor (anti-VEGF) drugs, on average, improved visual acuity. There was no difference among drugs in mean change in visual acuity from baseline among eyes with baseline Snellen equivalent visual acuity of 20/32 to 20/40, whereas aflibercept yielded ...
Source: Current Opinion in Ophthalmology - October 12, 2017 Category: Opthalmology Tags: Special Commentary Source Type: research

Treatment of cystoid macular edema secondary to retinitis pigmentosa: A systematic review
There are various treatments for cystoid macular edema (CME) secondary to retinitis pigmentosa (RP); however, the evidence for these treatments has not been previously systematically reviewed. Our review that includes 23 studies shows that oral carbonic anhydrase inhibitors (CAI) (including acetazolamide, methazolamide) and topical CAI (dorzolamide and brinzolamide) are effective first line treatments. In patients unresponsive to CAI treatment, intravitreal steroids (triamcinolone acetonide and sustained-release dexamethasone implant), oral corticosteroid (Deflazacort), intravitreal anti-vascular endothelial growth factor ...
Source: Survey of Ophthalmology - October 5, 2017 Category: Opthalmology Authors: Malini Bakthavatchalam, Frank H.P. Lai, Shi Song Rong, Danny S. Ng, Marten E. Brelen Tags: Reviews Source Type: research

Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review
There are various treatments for cystoid macular edema (CME) secondary to retinitis pigmentosa; however, the evidence for these treatments has not been previously systematically reviewed. Our review that includes 23 studies shows that oral carbonic anhydrase inhibitors (including acetazolamide and methazolamide) and topical carbonic anhydrase inhibitors (dorzolamide and brinzolamide) are effective first-line treatments. In patients unresponsive to carbonic anhydrase inhibitor treatment, intravitreal steroids (triamcinolone acetonide and sustained-release dexamethasone implants), oral corticosteroid (deflazacort), intravitr...
Source: Survey of Ophthalmology - October 5, 2017 Category: Opthalmology Authors: Malini Bakthavatchalam, Frank H.P. Lai, Shi Song Rong, Danny S. Ng, Marten E. Brelen Tags: Major review Source Type: research

Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
CONCLUSIONS: A single intravitreal dose of 0.2 mg (0.02 mL) ranibizumab showed favourable anatomical and functional outcomes in eyes with type 1 ROP. PMID: 28985806 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - October 1, 2017 Category: Opthalmology Authors: Ells AL, Wesolosky JD, Ingram AD, Mitchell PC, Platt AS Tags: Can J Ophthalmol Source Type: research

The Impact of The Rads Assessment: Can Fewer Injections With Intravitreal Aflibercept Translate To Lower Overall Treatment Burden and Costs In Wamd When Compared With Intravitreal Ranibizumab?
This study assessed, from the Danish perspective, the impact on the non-drug costs associated with different frequency for injections with IVT-AFL and ranibizumab. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Eriksson, L Hagelund, J Olsen, H Heemstra, J Carrasco Source Type: research

A case of choroidal neovascular membrane in 6-year-old boy with juvenile idiopathic arthritis
ConclusionsAlthough a rare complication, CNVM can occur in patients with JIA. (Source: Journal of Ophthalmic Inflammation and Infection)
Source: Journal of Ophthalmic Inflammation and Infection - September 30, 2017 Category: Opthalmology Source Type: research

Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization
Conclusion: Ranibizumab/bevacizumab therapy was effective in improving and maintaining visual acuity in myopic choroidal neovascularization. Early diagnosis, better baseline BCVA, and hyperfundus autofluorescence CNV pattern were strongly associated with better functional outcomes. Moreover, CNV distinguished by its small size and low CMT responded more favorably, achieving a better visual outcome. (Source: RETINA)
Source: RETINA - September 27, 2017 Category: Opthalmology Tags: Original Study Source Type: research

ASSOCIATIONS BETWEEN MACULAR EDEMA AND CIRCULATORY STATUS IN EYES WITH RETINAL VEIN OCCLUSION: An Adaptive Optics Scanning Laser Ophthalmoscopy Study
Conclusion: Using adaptive optics scanning laser ophthalmoscopy in eyes with retinal vein occlusion macular edema, we could quantitatively evaluate the parafoveal AEV. A reduction or an increase in parafoveal AEV may be a clinical marker for the resolution or development/progression of macular edema respectively. (Source: RETINA)
Source: RETINA - September 27, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Optical coherence tomography angiography changes in early type 3 neovascularization after anti-vascular endothelial growth factor treatment
Conclusion: Optical coherence tomography angiography showed that the tuft-shaped abnormal outer retinal lesion, frequently associated with a small clew-like flow signal in the choriocapillaris, after 1 year of anti–vascular endothelial growth factor therapy, either becomes undetectable or develops sub–retinal pigment epithelium neovascularization. (Source: RETINA)
Source: RETINA - September 27, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Choroidal thickness as a prognostic factor of photodynamic therapy with aflibercept or ranibizumab for polypoidal choroidal vasculopathy
Purpose: To investigate factors associated with visual improvement and retreatment 12 months after a combination therapy of intravitreal injection of ranibizumab or aflibercept followed by photodynamic therapy for polypoidal choroidal vasculopathy. Methods: Changes in the best-corrected visual acuity and the subfoveal thickness of the retina and choroid were studied in 56 consecutive eyes with polypoidal choroidal vasculopathy treated initially with a combination therapy of either intravitreal ranibizumab injection (n = 23) or intravitreal aflibercept injection (n = 33) followed by photodynamic therapy. Factors associated...
Source: RETINA - September 27, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab
Conclusion: The three anti-VEGF treatments examined in this analysis demonstrated notable differences in systemic PKs. Generally, the reduction in plasma free-VEGF levels correlated with elevated levels of circulating anti-VEGF agents, with the reduction in free-VEGF levels greatest with aflibercept and least with ranibizumab. (Source: RETINA)
Source: RETINA - September 27, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - September 27, 2017 Category: Opthalmology Authors: Justus G. Garweg Sophie A. Niderprim Hanna Maria Russ Isabel B. Pfister Source Type: research

Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents
Purpose: To compare changes of retinal morphology in the first weeks following injection of anti-VEGF agents for neovascular age-related macular degeneration (nAMD).Procedures: In a prospective study 50 patients with active choroidal neovascularization secondary to nAMD were monitored weekly by spectral-domain optical coherence tomography for 3 weeks after treatment. Twenty-two patients received bevacizumab, 15 ranibizumab, and 13 aflibercept. Morphological parameters of retinal compartments were compared.Results: Mean central retinal thickness (391.22 ± 123.41 µm) was reduced by -26.15 µm (p (Source: Ophthalmologica)
Source: Ophthalmologica - September 26, 2017 Category: Opthalmology Source Type: research

Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice
Purpose: Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab.Methods: We conducted a retrospective study evaluating outcomes of multiple DEX injections and those requiring conversion to ranibizumab at Moorfields Eye Hospital, Bedford, UK. All patients had undergone a complete ophthalmic work-up.Results: Patients (n = 129) had a mean follow-up of 19.9 months. The mean improvement in central retinal thickness was 312 μm after final DEX (p = (Source: Ophthalmologica)
Source: Ophthalmologica - September 26, 2017 Category: Opthalmology Source Type: research

Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study
W Gu & H Chen (Source: Eye)
Source: Eye - September 22, 2017 Category: Opthalmology Authors: J Cui D Sun H Lu R Dai L Xing H Dong L Wang D Wei B Jiang Y Jiao M M Jablonski S Charles W Gu H Chen Source Type: research

Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study
Eye, Published online: 22 September 2017; doi:10.1038/eye.2017.187 (Source: Eye)
Source: Eye - September 22, 2017 Category: Opthalmology Authors: J Cui D Sun H Lu R Dai L Xing H Dong L Wang D Wei B Jiang Y Jiao M M Jablonski S Charles W Gu H Chen Source Type: research

Alternative ways to optimize treatment for retinal vein occlusion with peripheral capillary non-perfusion: a pilot study
Conclusions: The combination of ranibizumab injections and peripheral SLP in capillary non-perfusion areas can significantly decrease the number of injections a nd reduce neovascular complications.RESUMO Objetivo: A investiga ção centra-se na terapia de edema macular pós-oclusão da veia retiniana central (OVCR) em casos com isquemia retiniana periférica. O objetivo foi comparar a eficácia e a segurança do tratamento com ranibizumab vs ranibizumab + fotocoagulação com laser de dispersão (SLP) em pacientes com ed ema macular crônico secundário...
Source: Arquivos Brasileiros de Oftalmologia - September 21, 2017 Category: Opthalmology Source Type: research

Intravitreal ranibizumab as an adjunctive treatment for coats disease (6-year follow-up)
Discussion: Elevated vascular endothelial growth factor levels have been demonstrated in Coats disease. Anti–vascular endothelial growth factor agents assist to the decrease of vascular permeability of the capillary endothelial cells, thus increasing the efficiency of laser application. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - September 20, 2017 Category: Opthalmology Tags: Case Report Source Type: research

Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child
Conclusion: Intravitreal ranibizumab can be considered as an adjunct therapy in proliferative retinopathy secondary to incontinentia pigmenti when monotherapy with panretinal photocoagulation fails. Intravitreal ranibizumab may quickly inhibit the intraocular vascular endothelial growth factor and may prevent devastating complications like tractional retinal detachment. Extra caution has to be taken in adopting different dosages and injection regimes especially in pediatric cases. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - September 20, 2017 Category: Opthalmology Tags: Case Report Source Type: research

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age ‐related macular degeneration
ConclusionAll these data suggest that genetics play an important role in treatment response in AMD patients. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 19, 2017 Category: Opthalmology Authors: Estefania Cobos, Sergio Recalde, Jaouad Anter, Maria Hernandez ‐Sanchez, Carla Barreales, Leticia Olavarrieta, Alicia Valverde, Marta Suarez‐Figueroa, Fernando Cruz, Maximino Abraldes, Julian Pérez‐Pérez, Patricia Fernández‐Robredo, Luis Arias, Tags: Original Article Source Type: research

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age ‐related macular degeneration
Acta Ophthalmologica,Volume 96, Issue 2, Page e201-e212, March 2018. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 19, 2017 Category: Opthalmology Source Type: research

Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion
ConclusionBoth RNB and DEX provided a significant resolution in macular oedema. Low frequency injections limited the visual gain in ranibizumab therapy. Visual results could be better with higher frequency injections and early start of treatment. Dexamethasone implants may be preferable in terms of visual improvement under low frequency injection conditions. Close follow‐up is mandatory for detection of intraocular pressure elevations. Laser monotherapy is not a reasonable first‐line option in the era of injection therapies. (Source: Clinical and Experimental Optometry)
Source: Clinical and Experimental Optometry - September 18, 2017 Category: Opthalmology Authors: Bora Yuksel, Omer Karti, Ozan Celik, Suleyman Gokhan Kerci, Tuncay Kusbeci Tags: Research Source Type: research

Photodynamic therapy in combination with Ranibizumab versus Ranibizumab monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis
(Source: Photodiagnosis and Photodynamic Therapy)
Source: Photodiagnosis and Photodynamic Therapy - September 18, 2017 Category: Laser Surgery Authors: Lei Liu, Yih-Chung Tham, Jingyang Wu, Song Yue, Ching-Yu Cheng Source Type: research

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience.
Authors: Ozkaya A, Alkin Z, Togac M, Ahmet S, Perente I, Taskapili M Abstract PURPOSE: To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration (nAMD) in a single center and real life clinical setting. METHODS: The records of nAMD patients who were treated with ranibizumab between January 2010 and June 2011 were retrospectively reviewed. Patients who completed 5 years of follow-up were included. Main outcome measures were change in best-corrected visual acuity, central retinal thickness, and visit and injection numbers. RESULTS: Forty-four eyes of 37 patients ...
Source: Korean Journal of Ophthalmology : KJO - September 17, 2017 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.
CONCLUSION: Switching to aflibercept in refractory DME results in significant functional and anatomical improvement. The study was approved by the France Macula Federation ethical committee (FMF 2017-138). PMID: 28900543 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - September 15, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema
Anti-vascular endothelial growth factor (VEGF) therapy has become the first-line choice for center-involved diabetic macular edema (DME) treatment.1 Currently, three anti-VEGF drugs are routinely used in DME treatment: bevacizumab (Avastin; Genentech, South San Francisco, CA), ranibizumab (Lucentis; Genentech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY). Of these, only ranibizumab and aflibercept have U.S. Food and Drug Administration (FDA) approval for the treatment of DME, whereas bevacizumab is used off-label.1 –4 Despite the efficacy of these drugs in the (Source: Ophthalmic Surger...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - September 14, 2017 Category: Opthalmology Authors: Touka Banaee, MD Source Type: research

Aflibercept in the management of acute retinal necrosis syndrome-related macular edema.
CONCLUSIONS: Intravitreal aflibercept is effective in the management of acute nontractional CME secondary to ARN. PMID: 28967076 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - September 14, 2017 Category: Opthalmology Authors: Ortega-Evangelio L, Navarrete-Sanchis J, Williams BK, Tomás-Torrent JM Tags: Eur J Ophthalmol Source Type: research

A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal.
CONCLUSION: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation. PMID: 28898611 [PubMed - in process] (Source: Acta Medica Portuguesa)
Source: Acta Medica Portuguesa - September 14, 2017 Category: General Medicine Tags: Acta Med Port Source Type: research

3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy
In conclusion, the 3D endothelial cell spheroid/human vitreous assay represents a rapid and cost-effective experimental procedure suitable for the evaluation of the anti-angiogenic activity of novel extracellular and intracellular drug candidates, with possible implications for the therapy of PDR. (Source: Angiogenesis)
Source: Angiogenesis - September 13, 2017 Category: Molecular Biology Source Type: research

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration
To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (TREND) study. (Source: Ophthalmology)
Source: Ophthalmology - September 8, 2017 Category: Opthalmology Authors: Rufino Silva, Andr ás Berta, Michael Larsen, Wayne Macfadden, Chrystel Feller, Jordi Monés, TREND Study Group Source Type: research

Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization
Purpose: To compare two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization.Methods: A total of 61 eyes of 56 patients were treated: 26 eyes received a single injection followed by treatment pro re nata (1+ PRN), while 35 eyes first received 3 consecutive monthly injections (3+ PRN).Results: The mean follow-up was 53 ± 16 months. The visual acuities were 51.9 ± 16.2 letters with 3+ PRN and 53 ± 22.4 letters with 1+ PRN at baseline (p = 0.824); 69.5 ± 12.3 and 69 ± 15.1 letters, respectively, at 12 months; and 67.1 ± 16.2 a...
Source: Ophthalmologica - September 7, 2017 Category: Opthalmology Source Type: research

Effects of VEGF levels on anti-VEGF therapy for patients with idiopathic choroidal neovascularization.
The objective of this study is to investigate the levels of vascular endothelial growth factor (VEGF) and other cytokines in aqueous humor of patients with idiopathic choroidal neovascularization (CNV) and their effects together with central retinal thickness (CRT) on the response to intravitreal injection of anti-VEGF antibody ranibizumab. This clinical study recruited 32 eyes from 32 patients with CNV under or besides fovea. VEGF, interleukin (IL)-6, IL-8, and monocyte chemoattractant protein (MCP)-1 levels were detected in aqueous humor (0.1 ml) sampled during intravitreal injection. Aqueous humor controls were fro...
Source: Molecular and Cellular Biochemistry - September 7, 2017 Category: Biochemistry Authors: Fan X, Gao N, Li J, Lei J, Kang Q Tags: Mol Cell Biochem Source Type: research